Germany's DMPs (disease management programmes) ready for take-off
This article was originally published in Clinica
Executive Summary
This week saw the launch of regulations for Germany's disease management programmes (DMPs), designed by health minister Ulla Schmidt to provide optimum care to the chronically ill. DMPs for the treatment of diabetes mellitus type II and breast cancer are the first of the initial five projects, planned over the past two years, to officially be given the go-ahead. "The regulations detail the requirements that these programmes must fulfil in order to be authorised by the federal department for insurance," said Ms Schmidt.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.